VK-2809

DB15137InvestigationalSmall molecule

VK-2809 is under investigation in clinical trial NCT02927184 (Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease).

Mechanism: Pharmacologically active on Thyroid hormone receptor beta
Curator reviewed
Formula / weight: C₂₈H₃₂ClO₅P · 514.98 g/mol (avg)
Code names: VK-2809

Resolves to

Compound

UNII3Z11398FNQCAS852948-13-1ChEMBLCHEMBL457748

Structure

InChIKeyLGGPZDRLTDGYSQ-JADSYQMUSA-NSMILESCC(C)C1=CC(CC2=C(C)C=C(OC[P@@]3(=O)OCC[C@H](O3)C3=CC=CC(Cl)=C3)C=C2C)=CC=C1O

Targets

P10828THRB

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with VK-2809, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account